Unhealthy Prognosis for Venture-Backed Diagnostics

Tim Gallagher shared with you: Some brilliant caution on molecular diagnostics from Bruce Booth. Turns out, MDx development is just about as risky and capital intensive as therapeutic development, with arguably less upside and liquidity.   Unhealthy Prognosis for Venture-Backed Diagnostics forbes.com